Dynavax Technologies (DVAX) Stock Rating Upgraded by BidaskClub
Dynavax Technologies (NASDAQ:DVAX) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.
A number of other analysts have also issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a report on Monday, October 1st. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, August 9th. Finally, ValuEngine lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $27.50.
Shares of NASDAQ DVAX opened at $11.29 on Thursday. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $776.43 million, a P/E ratio of -6.53 and a beta of 0.30. Dynavax Technologies has a 52-week low of $10.35 and a 52-week high of $23.85.
Institutional investors have recently bought and sold shares of the business. Gofen & Glossberg LLC IL purchased a new stake in Dynavax Technologies during the third quarter worth $145,000. Tiverton Asset Management LLC purchased a new stake in Dynavax Technologies during the second quarter worth $184,000. WINTON GROUP Ltd purchased a new stake in Dynavax Technologies during the first quarter worth $199,000. Xact Kapitalforvaltning AB purchased a new stake in Dynavax Technologies during the first quarter worth $200,000. Finally, Commonwealth Equity Services LLC purchased a new stake in Dynavax Technologies during the first quarter worth $212,000. Institutional investors own 82.02% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Recommended Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.